Brummer, Christina <br/><br/>
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.  [electronic resource] 

 -  Cancer letters  02 2019 
 - 453-463 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2018.11.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Inflammatory Agents, Non-Steroidal--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Diclofenac--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Energy Metabolism--drug effects<br/>Genetic Predisposition to Disease<br/>Humans<br/>Melanoma--drug therapy<br/>Mitogen-Activated Protein Kinases--antagonists & inhibitors<br/>Mutation<br/>Phenotype<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Skin Neoplasms--drug therapy<br/>Time Factors<br/>Vemurafenib--pharmacology